Physician profile
Anthony Macaluso
NPI 1649201385
$20,118.26
in general payments reported to CMS, 2019-2025
27 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $131 · 2021: $6,135 · 2022: $11K · 2023: $574 · 2024: $1,529 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801 · Travel and Lodging: $673 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.48 |
| Travel and Lodging | $673.19 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $18,056.61 | 2019-2024 | Da Vinci Surgical System |
| Ethicon US, LLC | $405.09 | 2024-2025 | Echelon Flex, Vistaseal, Echelon; Endopath |
| Axonics, INC. | $331.45 | 2022-2023 | Axonics |
| Medtronic, INC. | $271.28 | 2024 | Turbohawk |
| Abbott Laboratories | $133.13 | 2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $120.31 | 2023 | Shingrix |
| Sirtex Medical INC | $116.34 | 2019 | |
| Aimmune Therapeutics, INC. | $100.20 | 2024 | |
| Thd America, INC. | $98.33 | 2020 | |
| Smith+Nephew, INC. | $57.30 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.08 | 2023-2025 | Gattex |
| Conmed Corporation | $45.45 | 2019 | |
| Innovation Technologies INC | $35.18 | 2023 | Irrisept |
| Zyla Life Sciences, INC. | $30.47 | 2019 | |
| Myriad Genetic Laboratories, INC. | $29.83 | 2025 | Myrisk |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.01 | 2021 | |
| Activ Surgical, INC. | $28.41 | 2021 | |
| Acell, INC. | $26.33 | 2019-2020 | |
| Davol INC. | $24.22 | 2023 | Arista Ah Flexitip |
| Pacira Pharmaceuticals Incorporated | $20.57 | 2019 | |
| Cook Biotech Incorporated | $19.99 | 2023 | Biodesign |
| Acera Surgical, INC. | $17.00 | 2024 | Restrata Wound Matrix |
| Allergan, INC. | $15.22 | 2019 | |
| W. L. Gore & Associates, INC. | $15.20 | 2019 | |
| Covidien LP | $15.18 | 2019 | |
| Stryker Corporation | $14.74 | 2024 | |
| Integra Lifesciences Corporation | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Macaluso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.